Literature DB >> 27168103

Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity With Lanreotide Autogel/Depot (LAN) Versus Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27168103

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  4 in total

1.  Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study.

Authors:  M Albertelli; E Nazzari; S Sciallero; F Grillo; S Morbelli; F De Cian; G Cittadini; E Ambrosetti; A Ciarmiello; D Ferone
Journal:  J Endocrinol Invest       Date:  2017-05-26       Impact factor: 4.256

Review 2.  The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.

Authors:  Michael Michael; Rocio Garcia-Carbonero; Matthias M Weber; Catherine Lombard-Bohas; Christos Toumpanakis; Rodney J Hicks
Journal:  Oncologist       Date:  2017-02-20

3.  Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.

Authors:  Isabel Sevilla; Ángel Segura; Jaume Capdevila; Carlos López; Rocío García-Carbonero; Enrique Grande
Journal:  BMC Cancer       Date:  2016-11-07       Impact factor: 4.430

4.  Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate.

Authors:  Enrique Grande; Olga Martínez-Sáez; Pablo Gajate-Borau; Teresa Alonso-Gordoa
Journal:  World J Clin Oncol       Date:  2017-04-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.